Transition Therapeutics is looking for a new business partner, after an arrangement with drug giant Novo Nordisk went sour. Transition need research funding to develop their GLP1-I.N.T therapy. The company work on developing diabetes, Alzheimer’s, multiple sclerosis and hepatitis C treatments .
The islet neogenesis therapy has proved strikingly effective in animal studies according to Transition experts. The therapy works by inducing the generation of new insulin-producing cells. Novo Nordisk retain the rights to another Transition Therapy program, E1-I.N.T, after an investment of $1m.
The failure of the Novo arrangement came due to ‘priorities.’ Transition want to develop GLP1-I.N.T as quickly as possible, with one expert saying: “We needed to move GLP1-I.N.T. into diabetic patients as soon as possible; thus we had no option but to renegotiate the agreement with Novo Nordisk.” Apparently, Novo are now conducting a large phase 3 trial on inhalable insulin.
Transition remains confident that they will have positive news in the near future . The problem likely arose from the need for Transition to push their therapy through development . As a large company, Novo Nordisk could afford to move slower on the development, causing eventual conflict and the break down of the agreement.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…